New Horizons in Cancer Treatment: A Closer Look at Novel PI3Kα Inhibitors

Phosphoinositide 3-kinase (PI3K), a lipid messenger in cellular biology, regulates numerous cellular responses, including cell survival and migration. Abnormal activation of PI3K has been identified in many human tumors, implicating it as a pivotal point in cancer research. PI3K inhibitors have show...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2023-09, Vol.14 (9), p.1138-1140
Main Author: Kargbo, Robert B.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phosphoinositide 3-kinase (PI3K), a lipid messenger in cellular biology, regulates numerous cellular responses, including cell survival and migration. Abnormal activation of PI3K has been identified in many human tumors, implicating it as a pivotal point in cancer research. PI3K inhibitors have shown promise in controlling tumor progression and chemotherapy resistance. However, challenges like cutaneous adverse effects require further research. The PI3K signaling pathway’s role in cellular processes, such as aging and Alzheimer’s disease progression, also signifies its importance in drug development for aging-related diseases. Future research promises innovative therapeutic strategies targeting PI3K in managing cancer, aging, and neurodegenerative diseases. This Patent Highlight showcases compounds and compositions that may enlarge the PI3K inhibitory therapeutic windoweffectively inhibiting the target in cancer cells while reducing toxicity in patients.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.3c00307